Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

Verastem Oncology appointed board member Michael P. Bailey as President and CEO effective January 1, 2027, succeeding Daniel Paterson, who retires after leading the company as CEO since 2023. Paterson led the acquisition and FDA accelerated approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent LGSOC and advanced VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, into Phase 2 trials and toward a planned Phase 3 in first-line metastatic pancreatic cancer.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.